Ibrutinib CAS 936563-96-1 Purity >99.5% (HPLC) API

Short Description:

Chemical Name: Ibrutinib 

CAS: 936563-96-1

Purity: >99.5% (HPLC)

Appearance: White to Off-White Crystal Powder

Ibrutinib is a BTK inhibitor used to treat Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) 

Contact: Dr. Alvin Huang   

Mobile/Wechat/WhatsApp: +86-15026746401   

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Description:

Chemical Properties:

Chemical Name Ibrutinib
Synonyms 1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one; PCI-32765
CAS Number 936563-96-1
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C25H24N6O2
Molecular Weight 440.50
Brand Ruifu Chemical

Specifications:

Item Specifications
Appearance White to Off-White Crystal Powder  
Identification IR; HPLC
Loss on Drying <0.50%
Residue on Ignition ≤0.10%
Heavy Metals (as Pb) ≤20ppm
Any Single Impurity ≤0.20%
Total Impurities <0.50%
Purity / Analysis Method >99.5% (HPLC)
Test Standard Enterprise Standard
Usage API

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.

Advantages:

1

FAQ:

Application:

Ibrutinib (CAS: 936563-96-1) is an inhibitor of Bruton tyrosine kinase (BTK) for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Both MCL and CLL belong to B-cell non-Hodgkin's lymphoma, which is refractory and prone to relapse. The commonly used chemoimmunotherapy is not targeted, and grade 3 or 4 adverse reactions often occur. Ibrutinib can combine with BTK, which is necessary for the formation, differentiation, communication and survival of B lymphocytes, and irreversibly inhibit the activity of BTK, effectively inhibit the proliferation and survival of tumor cells. In addition, it is rapidly absorbed after oral administration, the maximum plasma concentration is reached 1~2h, and the adverse reactions are grade 1 or 2, which will become a new option for the treatment of CLL and MCL. On November 13, 2013, the U.S. FDA to accelerate the approved Johnson & Johnson company and the United States Imbruvica (common name: Ibrutinib) for the treatment of mantle cell lymphoma (MCL). Ibrutinib, was granted breakthrough Therapy status by the FDA in February 2013 and was approved for MCL on November 13, 2013 and CLL on February 12, 2014, respectively.

  • Write your message here and send it to us